Graminex® Rye Pollen Achieves Novel Food Registration in China and Appoints Guangzhou Narnia Biotechnology as Their Authorized Distribution Partner
Graminex® announced today that it has achieved novel food registration in China for Rye Pollen and appointed Guangzhou Narnia Biotechnology as its distribution partner in China.
Graminex®, based in the United States, is the exclusive grower and manufacturer of rye pollen and a leader in the international dietary supplement industry, with products sold in more than 47 countries. Graminex’s vertically integrated manufacturing ensures quality, consistency, and efficacy of their products. Guangzhou Narnia Biotech will represent Graminex® Rye Pollen active ingredients, as well as the dietary supplements, primarily focusing on the areas of prostate health, women’s health, and liver support.
“We are very excited about the opportunity to market high quality dietary ingredients that have been recently registered in China,” said Daniel Guo, General Manager, Narnia Biotech. “Our market is increasingly looking for high-quality dietary products. Our cooperation with Graminex® will strengthen Narnia’s offering to our customers and is in line with Narnia’s strategy of partnering with innovative producers of unique ingredients.”
Heather J. May, CEO of Graminex® said, “Narnia Biotech has a reputation of unmatched customer service and technical capabilities, including lab testing and product formulation. I am confident that through their expertise and attention to product safety and quality assurance, they are the right distribution partner for Graminex in China.”
About Guangzhou Narnia Biotechnology Co., Ltd
Narina is headquartered in TIMES E-PARK, Tianhe District, Guangzhou, with an R&D Center in Guangzhou. Its branch in Beijing extends their network throughout China. Narnia’s mission to create a safe, natural, and nutritious life is based on commitments to integration and promotion of functional food ingredients. With current market trends and continuously developing formulation technology, Narnia provides customers one-stop procurement solutions, as well as value-added services such as market analysis, project launching, formula design, and production guidance. Visit www.narniabiotech.com.
About Graminex ® L.L.C.
Graminex® is the leading producer of solvent-free Graminex® Rye Pollen. Graminex® owns and manages over 6,500 farm acres in Ohio to meet customer’s needs. Graminex’s active ingredients are grown and processed for the dietary supplement, nutraceutical, pharmaceutical, food and skincare industries, focusing on prostate health, urinary care, menopausal support. Visit www.graminex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230807107912/en/
Contact information
Colleen E. May
CBO
+1 (419) 278-1023
graminex@graminex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe1.12.2025 08:00:00 EET | Press release
Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and Xgeva. The products will be commercially available in Europe in December 2025 and January 2026, respectively. “We are very thrilled to launch OBODENCE and XBRYK through our direct sales efforts. Osteoporosis remains a major challenge in Europe due to limited treatment options and affordability challenges. And bone-related events resulting from bone metastases significantly impact a patient's quality of life, leading to death if not treated fast enough. Our biosimilars aim to improve access, enable timely care, and ease the financial burden on healthcare systems.”, said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial Division at Samsung Bioepis. “With our proven track records, we’re confident that OBODENCE and XBRYK will deliver meaningful impact on patients and their communities.” OBODENCE, refer
UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs28.11.2025 23:31:00 EET | Press release
The UAE’s Artificial Intelligence, Digital Economy, and Remote Work Applications Office announced that Google Gemini has ranked first in the “AI in the Ring” Index, the world’s first benchmark designed to evaluate how effectively AI language models reflect Emirati culture, dialects, traditions, and national values through a challenge centered on cultural intelligence within the UAE context. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251128785463/en/ UAE announces Google Gemini Is Now the Most Culturally Accurate AI for Arabs (Photo: AETOSWire) Gemini earned the top ranking following a review of over 400 questions across 7 cultural dimensions and 5,200 generated responses from 11 major language models. A Committee of Emirati experts evaluated the outputs to identify which models demonstrated the strongest cultural understanding. Following Gemini 2.5 Pro, the list of the top five high-performing models included: ChatGPT (O
GE HealthCare announces CE Mark for the Omni 128cm total body PET/CT system28.11.2025 13:00:00 EET | Press release
GE HealthCare today announced CE Mark for its next-generation Omni 128cm total body positron emission tomography / computed tomography (PET/CT) system,i a major milestone in its mission to advance precision care. Designed to advance cancer diagnosis, staging, therapeutic planning and treatment response monitoring, this innovative system represents a leap forward in molecular imaging capabilities and clinical efficiency. As global cancer rates continue to rise – projected to increase 77 percent by 2050ii – the need for advanced imaging solutions has never been greater. The growing prevalence of cancer and emergence of investigational immunotherapies and targeted treatments have accelerated the demand for whole-body PET/CT imaging. GE HealthCare’s new technology is built to meet this need, supporting theranostics and enabling clinicians to visualize, diagnose and monitor disease with impressive precision and speed. “Our commitment to precision health is rooted in innovation that also aim
King Abdulaziz Foundation Organizes the First Edition of the Forum on the “History of Hajj and the Two Holy Mosques” in Jeddah28.11.2025 11:53:00 EET | Press release
King Abdulaziz Foundation (Darah) held the first edition of the Forum on the “History of Hajj and the Two Holy Mosques”, convened as part of the program of the “Hajj Conference and Exhibition 2025” at the Super Dome Hall in Jeddah, in cooperation with the Ministry of Hajj and Umrah and the Guests of God Service Program, during the period from 9–12 November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251128600368/en/ King Abdulaziz Foundation Organizes the First Edition of the Forum on the “History of Hajj and the Two Holy Mosques” in Jeddah (Photo: AETOSWire) The forum’s activities were inaugurated following the announcement by His Royal Highness Prince Faisal bin Salman bin Abdulaziz Al Saud, Special Advisor to the Custodian of the Two Holy Mosques and Chairman of the Board of Directors of the King Abdulaziz Foundation, who declared the launch of the forum during the opening ceremony of the “Hajj Conference and Exh
VSO Unveils VCP v1.0, a First-of-Its-Kind Cryptographic Audit Protocol to Restore Trust in AI-Driven Markets28.11.2025 07:30:00 EET | Press release
The VeritasChain Standards Organization (VSO), an independent international standards body, today announced the global release of VeritasChain Protocol (VCP) v1.0, an open cryptographic audit protocol designed to provide mathematically provable transparency for AI‑driven and algorithmic trading systems. VCP replaces mutable server logs with a tamper‑evident chain of cryptographic evidence, enabling regulators, brokers, exchanges and trading firms to move from trust‑based oversight to verification‑based supervision. Why This Matters Now The launch of VCP v1.0 comes at a pivotal moment for global market infrastructure: More than 80 proprietary trading firms collapsed between 2024 and 2025 amid regulatory scrutiny, opaque execution models and frozen payout disputes, leaving a trust gap between traders and platforms. Regulators worldwide are tightening expectations around algorithmic accountability — from U.S. enforcement actions against high‑risk retail FX schemes to the EU AI Act (high‑r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom